Zobrazeno 1 - 10
of 284
pro vyhledávání: '"Avitinib"'
Autor:
Yang Miao, Yanhua Wang, Zhun Bi, Kai Huang, Jingjing Gao, Xiaohe Li, Shimeng Li, Luqing Wei, Honggang Zhou, Cheng Yang
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterized by alveolar epithelial cell injury and lung fibroblast overactivation. At present, only two drugs are approved by the FDA for the treatment
Externí odkaz:
https://doaj.org/article/877d1d3af1684284b7ea65d76717d765
Autor:
Wu, Qingjun1 (AUTHOR) wooqj_bj@126.com, Jiang, Hui2 (AUTHOR), Wang, Shuanghu2 (AUTHOR), Dai, Dapeng3 (AUTHOR), Chen, Feifei2 (AUTHOR), Meng, Deru2 (AUTHOR), Geng, Peiwu2 (AUTHOR), Tong, Hongfeng1 (AUTHOR), Zhou, Yunfang2 (AUTHOR), Pan, Debiao4 (AUTHOR) pandebiao@163.com, Zhou, Quan2 (AUTHOR) zhouquan1991@lsu.edu.cn, Wang, Chunjie5 (AUTHOR) 1024172645@qq.com
Publikováno v:
Thoracic Cancer. Oct2020, Vol. 11 Issue 10, p2775-2781. 7p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Qingjun Wu, Hui Jiang, Shuanghu Wang, Dapeng Dai, Feifei Chen, Deru Meng, Peiwu Geng, Hongfeng Tong, Yunfang Zhou, Debiao Pan, Quan Zhou, Chunjie Wang
Publikováno v:
Thoracic Cancer, Vol 11, Iss 10, Pp 2775-2781 (2020)
Background Avitinib is one type of the third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer (NSCLC) with EGFR mutations. The purpose of this study was to invest
Externí odkaz:
https://doaj.org/article/dd9cb7cdd61e459e8fb2c6533a6cf9b3
Publikováno v:
In Journal of Pharmaceutical and Biomedical Analysis 5 February 2019 164:659-667
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 15, Pp 3661-3673 (2021)
Yong Shi,1,* Deru Meng,1,* Shuanghu Wang,1 Peiwu Geng,1 Tao Xu,2 Quan Zhou,1 Yunfang Zhou,1 Wanshu Li,3 Xugao Chen4 1Comprehensive Breast Health Center, Department of Thyroid and Breast Surgery, The Sixth Affiliated Hospital of Wenzhou Medica
Externí odkaz:
https://doaj.org/article/e19d1850d8a04e3ab92c95404cd7779c
Publikováno v:
In Journal of Pharmaceutical and Biomedical Analysis 30 May 2017 139:205-214
Autor:
Yunfang Zhou, Qingjun Wu, Hongfeng Tong, Shuanghu Wang, Debiao Pan, Peiwu Geng, Deru Meng, Chunjie Wang, Feifei Chen, Quan Zhou, Dapeng Dai, Hui Jiang
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 10, Pp 2775-2781 (2020)
Thoracic Cancer, Vol 11, Iss 10, Pp 2775-2781 (2020)
Background Avitinib is one type of the third‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer (NSCLC) with EGFR mutations. The purpose of this study was to invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::905dd2eb4ae69e80c7488732357d9ffe
https://doi.org/10.1111/1759-7714.13587
https://doi.org/10.1111/1759-7714.13587
Autor:
Miao, Yang, Wang, Yanhua, Bi, Zhun, Huang, Kai, Gao, Jingjing, Li, Xiaohe, Li, Shimeng, Wei, Luqing, Zhou, Honggang, Yang, Cheng
Additional file 2: Fig S1. In vivo and in vitro experimental schemes in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a78f82fd9d83bfd9cfcdb9285228a75
